Pharmacology of thrombolytic agents. Implications for therapy of coronary artery thrombosis.

Abstract

The potential for rapidly dissolving coronary artery thrombi and for decreasing the risk of mortality after myocardial infarction by use of thrombolytic therapy is considerable. However, data are insufficient regarding the relative efficacy of regional vs systemic administration, the proper dose of activator administered regionally, the therapeutic role of the plasma lytic state during regional therapy, the incidence of serious bleeding, and the potential for simpler therapy using new activators with fibrin specificity.

• Authors: V J Marder
• Journal: Circulation (Circulation) Vol. 68 Issue 2 Pt 2 Pg. I2-5 (Aug 1983) ISSN: 0009-7322 [Print] United States
• PMID: 6683134 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Fibrinolytic Agents
• Streptokinase
• Plasminogen Activators
• Urokinase-Type Plasminogen Activator

Topics

• Coronary Disease (drug therapy)
• Fibrinolytic Agents (administration & dosage, adverse effects, pharmacology, therapeutic use)
• Hemorrhage (chemically induced)
• Humans
• Myocardial Infarction (drug therapy)
• Plasminogen Activators (pharmacology)
• Streptokinase (pharmacology)
• Urokinase-Type Plasminogen Activator (pharmacology)